Clinical Trials Logo

Filter by:
NCT ID: NCT00625664 Completed - Clinical trials for Urinary Bladder Neoplasms

Larotaxel + Cisplatin Versus Gemcitabine + Cisplatin in First Line Treatment of Locally Advanced/Metastatic Urothelial Tract or Bladder Cancer

CILAB
Start date: February 2008
Phase: Phase 3
Study type: Interventional

This is a randomized, open-label, multi-center study comparing the efficacy and safety of XRP9881 plus cisplatin to gemcitabine plus cisplatin in the first line treatment of locally advanced/metastatic urothelial tract or bladder cancer. The primary objective is to compare overall survival. Secondary objectives include comparisons of progression free survival, objective response rate, time to definitive deterioration of performance status, duration of response, time to definitive weight loss, and assessments of overall safety, and pharmacokinetics. Patients are treated until disease progression, death, or unacceptable toxicity and are followed-up until death or the end of the study whichever comes first.

NCT ID: NCT00625547 Completed - Clinical trials for Restless Legs Syndrome

A Study to Determine the Efficacy and Safety of Cabergoline for the Treatment of Patients With RLS

Start date: January 2003
Phase: Phase 3
Study type: Interventional

The purpose of this study is to evaluate the efficacy and safety of cabergoline compared with levodopa in the treatment of patients with RLS.

NCT ID: NCT00625521 Completed - Clinical trials for Discoid Lupus Erythematosus

Efficacy and Safety of ASF-1096 Cream 0.5% in the Treatment of Discoid Lupus Erythematosus (DLE) Lesions

Start date: November 2006
Phase: Phase 2
Study type: Interventional

Lupus Erythematosus (LE) is an autoimmune disorder that includes a broad spectrum of clinical forms. One of these forms, Discoid Lupus Erythematosus (DLE) is a chronic disfiguring disease confined to the skin. The aim of this pivotal trial is to investigate the efficacy and safety of ASF-1096 cream 0.5% in the treatment of patients with DLE or SLE presenting newly developed discoid lesions.

NCT ID: NCT00624689 Completed - Infant Clinical Trials

Effects of Milk Fat Globule Membrane (MFGM) - Enriched Formula With Reduced Energy and Protein Content on Growth and Development

TUMME
Start date: March 2008
Phase: N/A
Study type: Interventional

Formula-fed infants differ from breast-fed infants in the growth pattern, risk for obesity and cardiovascular diseases, neurological development and morbidity in infections. The investigators' hypothesis is that a modified formula with reduced energy and protein content and enrichment with Milk Fat Globule Membrane (MFGM) containing bioactive proteins and phospholipids will reduce the difference between formula-fed and breast-fed infants.

NCT ID: NCT00623779 Completed - Clinical trials for Persistent or Permanent Non-valvular Atrial Fibrillation

Atrial Fibrillation (AF) Patients Not Taking Vitamin-K Antagonist (VKA)

Start date: October 2007
Phase: Phase 2
Study type: Interventional

The purpose of this study is to assess the safety and tolerability of AZD0837 in patients with atrial fibrillation who are unable or unwilling to take vitamin K antagonist therapy for up to 3 months.

NCT ID: NCT00622869 Completed - Clinical trials for Liver Transplantation

Efficacy and Safety of Concentration-controlled Everolimus to Eliminate or to Reduce Tacrolimus Compared to Tacrolimus in de Novo Liver Transplant Recipients

RAD
Start date: January 2008
Phase: Phase 3
Study type: Interventional

This trial was designed to address important issues that impact recipients of liver allografts as well as clinicians, ie, renal function, reduction or discontinuation of tacrolimus early post-transplantation, and progression rate of fibrosis in hepatitis C virus (HCV) positive patients.

NCT ID: NCT00622765 Completed - Obesity Clinical Trials

A Study of the Safety and Effectiveness of JNJ-16269110 (R256918) in Overweight and Obese Patients

Start date: November 2007
Phase: Phase 2
Study type: Interventional

This study investigates the effectiveness and safety of 12 weeks of treatment with JNJ-16269110 (R256918), in overweight and obese patients. The primary measure of effectiveness is the change in body weight at a clinically relevant dosage level during treatment. Additional measures include body mass index (BMI), DEXA (dual X-ray absorptiometry which is a specialized x-ray test that measures body composition), fasting glucose, lipid levels, and blood pressure. Safety assessments performed during the trial include laboratory tests, vital sign measurements, and adverse event reporting.

NCT ID: NCT00622583 Completed - Hernia Clinical Trials

International Hernia Mesh Registry

IHMR
Start date: September 1, 2007
Phase:
Study type: Observational

This is an open-label, multi-center, long-term, prospective hernia mesh registry. A minimum of 4,800 hernia patients will be enrolled from approximately 60 active sites globally

NCT ID: NCT00622284 Completed - Clinical trials for Diabetes Mellitus, Type 2

Efficacy and Safety of BI 1356 in Combination With Metformin in Patients With Type 2 Diabetes

Start date: February 2008
Phase: Phase 3
Study type: Interventional

The objective of the current study is to investigate the efficacy, safety and tolerability of BI 1356 (5.0 mg daily) compared to glimepiride given for 104 weeks as add-on therapy to preferably > 1500 mg metformin in patients with type 2 diabetes mellitus with insufficient glycaemic control

NCT ID: NCT00622245 Terminated - Clinical trials for Depression in Patients With Bipolar Disorder

Efficacy and Safety of Lu AA34893 in Patients With Bipolar Depression

Start date: January 2008
Phase: Phase 2
Study type: Interventional

This study will evaluate the efficacy and safety of different doses of Lu AA34893 in the treatment of depression in patients with bipolar disorder.